CHF Solutions Competitors

CHF Solutions (NASDAQ:CHFS) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and Medtronic, as provided by MarketBeat.com.

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 0.41%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than Medtronic.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and Medtronic's revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares CHF Solutions and Medtronic's net margins, return on equity and return on assets.

Summary

Medtronic beats CHF Solutions on 10 of the 15 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and Varian Medical Systems, as provided by MarketBeat.com.

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. Varian Medical Systems has a consensus price target of $159.3571, suggesting a potential downside of 10.02%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than Varian Medical Systems.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 87.0% of Varian Medical Systems shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 0.8% of Varian Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and Varian Medical Systems' revenue, earnings per share (EPS) and valuation.

Varian Medical Systems has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Profitability

This table compares CHF Solutions and Varian Medical Systems' net margins, return on equity and return on assets.

Summary

Varian Medical Systems beats CHF Solutions on 9 of the 14 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and Masimo, as provided by MarketBeat.com.

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. Masimo has a consensus price target of $272.20, suggesting a potential upside of 14.69%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than Masimo.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 81.6% of Masimo shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 11.5% of Masimo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and Masimo's revenue, earnings per share (EPS) and valuation.

Masimo has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares CHF Solutions and Masimo's net margins, return on equity and return on assets.

Summary

Masimo beats CHF Solutions on 11 of the 14 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and LivaNova, as provided by MarketBeat.com.

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. LivaNova has a consensus price target of $69.3333, suggesting a potential downside of 15.99%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than LivaNova.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CHF Solutions and LivaNova's revenue, earnings per share (EPS) and valuation.

CHF Solutions has higher earnings, but lower revenue than LivaNova. CHF Solutions is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares CHF Solutions and LivaNova's net margins, return on equity and return on assets.

CHF Solutions (NASDAQ:CHFS) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares CHF Solutions and CONMED's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CHF Solutions and CONMED, as provided by MarketBeat.com.

CHF Solutions currently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. CONMED has a consensus price target of $104.60, suggesting a potential downside of 20.56%. Given CHF Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe CHF Solutions is more favorable than CONMED.

Risk and Volatility

CHF Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Valuation and Earnings

This table compares CHF Solutions and CONMED's revenue, earnings per share (EPS) and valuation.

CONMED has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.1% of CHF Solutions shares are held by institutional investors. 0.6% of CHF Solutions shares are held by company insiders. Comparatively, 5.4% of CONMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CONMED beats CHF Solutions on 8 of the 13 factors compared between the two stocks.

CHF Solutions (NASDAQ:CHFS) and InMode (NASDAQ:INMD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Profitability

This table compares CHF Solutions and InMode's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for CHF Solutions and InMode, as provided by MarketBeat.

CHF Solutions presently has a consensus price target of $20.00, suggesting a potential upside of 266.97%. InMode has a consensus price target of $71.50, suggesting a potential downside of 14.90%. Given CHF Solutions' higher probable upside, equities analysts clearly believe CHF Solutions is more favorable than InMode.

Volatility and Risk

CHF Solutions has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500.

Valuation & Earnings

This table compares CHF Solutions and InMode's revenue, earnings per share and valuation.

InMode has higher revenue and earnings than CHF Solutions. CHF Solutions is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.1% of CHF Solutions shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 0.6% of CHF Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

InMode beats CHF Solutions on 10 of the 13 factors compared between the two stocks.